Emeis Q1 sales up 6.2% as occupancy rises, nursing homes lead growth

Published 12/05/2025, 10:32
© Reuters.

Investing.com -- Emeis (EPA:EMEIS) on Monday reported a strong start to 2025, with organic sales rising 6.2% and average occupancy increasing by two percentage points to 87%, aided by improved performance in nursing homes and across its international operations.

Group sales reached €1.45 billion in the first quarter, up 5.2% year-on-year on a reported basis and 6.2% on an organic basis, according to the company’s quarterly statement. 

Growth was attributed to a favorable price effect contributing 3.7 percentage points, a rise in occupancy rates adding 1.8 points, and the contribution of newly opened sites accounting for another 0.8 points.

Nursing homes, which represent nearly two-thirds of Emeis’ business, were the primary driver of growth, with organic sales up 9.6% compared with the first quarter of 2024. 

The average occupancy rate for nursing homes rose to 86.4%, an increase of 2.1 percentage points from the previous year.

The Group’s average occupancy rate across all segments reached 87.0%, compared with 85.0% at the end of March 2024 and 83.0% in the same period of 2023. On a mature facility basis, excluding recently opened or restructured sites, occupancy was 88.0%.

International markets recorded strong performances. Organic growth reached 11.4% in Northern Europe, 9.5% in Central Europe, and 10.3% in Southern Europe and Latin America. 

Central Europe, where occupancy rates approached 92%, showed the most marked improvement, while Northern Europe saw a three-point increase in occupancy to 85.3%. 

In Southern Europe and Latin America, the adjusted occupancy rate on mature facilities stood at 91.9%, up 2.9 points from the first quarter of 2024.

In France, which accounts for 41% of Group sales, the average occupancy rate reached 87.6%, up 1.7 points. 

Nursing homes in France saw occupancy rise 1.6 points to 83.5%, with organic sales up 3.6%, supported by both pricing and volume. 

Adjusted for a non-recurring positive effect in the first quarter of 2024, organic growth in French retirement homes would have reached 4.0%.

Clinic operations remained broadly stable overall, with organic sales declining 0.4% year-on-year. 

In France, clinics posted a 2.7% decline in organic sales, due to a lower number of full hospitalization days and a high comparable base in early 2024. This affected the volume of business, particularly in private rooms.

The company aims to complete €1.5 billion in divestments between mid-2022 and the end of 2025 to reduce debt. 

Ongoing negotiations cover more than €2 billion in potential transactions, exceeding the remaining target and offering flexibility in execution, the company said.

Emeis confirmed its guidance for 2025. It expects EBITDAR to rise between 15% and 18% on a like-for-like basis, excluding the impact of any operational disposals, building on the momentum observed since the second half of 2024.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.